Home » Stocks » Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC (AVDL)

Stock Price: $8.48 USD 0.24 (2.91%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 492.93M
Revenue (ttm) 55.02M
Net Income (ttm) -21.07M
Shares Out 58.13M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $8.48
Previous Close $8.24
Change ($) 0.24
Change (%) 2.91%
Day's Open 8.57
Day's Range 8.39 - 8.87
Day's Volume 655,386
52-Week Range 1.82 - 13.49

More Stats

Market Cap 492.93M
Enterprise Value 505.52M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.13M
Float 39.20M
EPS (basic) -0.56
EPS (diluted) -0.55
FCF / Share -0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.17M
Short Ratio 7.68
Short % of Float n/a
Beta 1.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.96
PB Ratio 14.52
Revenue 55.02M
Operating Income -21.25M
Net Income -21.07M
Free Cash Flow -28.60M
Net Cash -12.58M
Net Cash / Share -0.22
Gross Margin 85.59%
Operating Margin -38.63%
Profit Margin -38.30%
FCF Margin -51.98%
ROA -5.21%
ROE -187.44%
ROIC -10.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(115.21% upside)
Current: $8.48
Target: 18.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-42.66%-40.39%15.31%-13.16%1055.32%258.34%-44.53%-76.89%-12.12%-
Gross Profit47.0985.7515713716211.593.627.1326.3230.18
Operating Income-23.27-12858.4744.32102-33.15-25.57-28.75-9.58-9.84
Net Income-33.23-95.3068.27-41.2841.80-85.47-42.93-3.23-8.77-8.98
Shares Outstanding37.4037.3340.4741.2540.5836.2125.4525.1424.6724.41
Earnings Per Share-0.89-2.551.63-1.000.96-2.36-1.69-0.13-0.36-0.37
Operating Cash Flow-38.33-82.7216.6618.9084.29-10.62-20.68-23.14-10.32-5.46
Capital Expenditures0.13-0.18-0.59-1.20-1.6311.51-0.02-1.00-1.72-3.47
Free Cash Flow-38.20-82.8916.0717.7082.660.90-20.70-24.14-12.04-8.93
Cash & Equivalents64.1699.9294.0815414592.837.049.1624.4931.34
Total Debt12513574.191361.123.7285.5536.894.064.06
Net Cash / Debt-60.49-35.3319.8918.2114489.12-78.51-27.7320.4327.29
Book Value-29.202.7885.5842.0769.1324.90-9.5130.5029.7936.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avadel Pharmaceuticals PLC
Country Ireland
Employees 50
CEO Gregory J. Divis

Stock Information

Ticker Symbol AVDL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AVDL
IPO Date June 7, 1996


Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.